We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Beta glucan Helps Cells Get to Infection Site

By HospiMedica staff writers
Posted on 13 Oct 2004
Researchers have discovered further evidence that beta glucan enhances the ability of certain human immune cells to navigate to the site of a bacterial infection. More...
The findings were reported in the August 2004 issue of Surgery.

Beta Glucan binds to receptors (CR3) on neutrophils, the most abundant type of innate cell in the body, and benefits the host defense in two ways. One is by increased killing capacity of the neutrophils, and the other is migration or chemotaxis to the site of an infection or challenge. The neutrophils are attracted to the site of infection by blood proteins called chemoattractants and are among the first cells to respond to a challenge due to infection or injury.

Priming the neutrophils with beta glucan increases their ability to sense complement fragments emanating from an infection site. As a result, beta glucan helps neutrophils locate the bacterial mother lode within infected tissue. This more-rapid response to infection results in faster microbial clearance and healing.

The research was led by Dr. Jonathan Reichner, Ph.D., an associate professor of surgery at Rhode Island Hospital and associate director of the pathobiology graduate program at Brown University (both in Providence, USA). For the past 15 years, Dr. Reichner has been studying the ability of beta glucan to enhance the immune system to fight infectious diseases. The beta glucan used in the studies was from Biopolymer Engineering, Inc. (Eagan, MN, USA).




Related Links:
Brown University

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
IV Therapy Cart
Avalo I.V Therapy Cart
MRI System
nanoScan MRI 3T/7T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.